Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
5-aminolaevulinic acid (Ameluz®) is recommended as an option for use within NHS Wales for the treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to possible treatment related morbidity and/or poor cosmetic outcome in adults. |
|||
|
|||
Medicine details |
|||
| Medicine name | 5-aminolaevulinic acid (Ameluz®) | ||
| Formulation | 78 mg/g gel | ||
| Reference number | 3372 | ||
| Indication | Treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to possible treatment-related morbidity and/or poor cosmetic outcome in adults |
||
| Company | Biofrontera | ||
| BNF chapter | Skin | ||
| Assessment type | Full | ||
| Status | Recommended | ||
| Advice number | 2217 | ||
| NMG meeting date | 06/09/2017 | ||
| AWMSG meeting date | 11/10/2017 | ||
| Date of issue | 19/10/2017 | ||
| Date of last review | October 2020 | ||